http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
양덕환,정성훈,안재숙,김여경,민정준,범희승,이제중,김형준 전남대학교 의과학연구소 2015 전남의대학술지 Vol.51 No.3
The prognostic value of whole-body positron emission tomography/computed tomography(PET/CT) with 18F-fluoro-2-deoxy-D-glucose (FDG) shortly after the onset of inductionchemotherapy or mid treatment could help to predict long-term clinical outcomesin patients with Hodgkin’s or Non-Hodgkin’s lymphoma. However, FDG is nota tumor-specific substance, and it may accumulate to the point of being detected in avariety of benign conditions or at physiologic anatomical sites, which may give rise tofalse-positive interpretation. In an attempt to standardize the reporting criteria for interimPET/CT, the First International Workshop on Interim PET in Lymphoma suggestedvisual response criteria with the Deauville five-point scale, and the standardizeduptake value (SUV) has been investigated in comparison with this visual system. Aquantitative approach using the measurement of maximal SUV (SUVmax) or the reductionrate of SUVmax (ΔSUVmax) might be more appropriate in early-responsePET/CT for reducing false-positive rates or for decreasing interobserver variability ininterpretation. In this review, the predictive efficacy of PET/CT is discussed for thetreatment of aggressive lymphoma, especially in terms of an interim PET/CT-basedprognostic model.
이세련,양덕환,안재숙,김여경,이제중,최영진,신호진,정주섭,조윤영,김종광,손상균,김형준,채이수 대한의학회 2009 Journal of Korean medical science Vol.24 No.3
A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 ㎎/㎡, days 1-5), cytarabine (2.0 g/㎡, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (≥500/μL) and platelets (≥20,000/μL) required a median of 21 and 18 days, respectively. Treatmentrelated mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.